Table 4.

Significant difference in the effects on schizophrenia between clozapine and haloperidol

		European-Americans (n=127).				African-Americans (n=54).				Combined sample (n=181).
PANSS	Treatment	Size	Responser	Reduction	p	Size	Responser	Reduction	p	Size	Responser	Reduction	p
Total	Clozapine	58	0.397	0.171 ± 0.221		27	0.593	0.225 ± 0.206		85	0.459	0.188 ± 0.217
	Haldal	69	0.333	0.080 ± 0.228	0.025	27	0.333	0.115 ± 0.235	0.073	96	0.333	0.090 ± 0.230	0.004
Positive	Clozapine	58	0.586	0.245 ± 0.297		27	0.741	0.307 ± 0.297		85	0.635	0.265 ± 0.296
	Haldal	69	0.420	0.142 ± 0.365	0.089	27	0.444	0.148 ± 0.315	0.062	96	0.427	0.144 ± 0.350	0.014
Negative	Clozapine	58	0.345	0.092 ± 0.303		27	0.481	0.129 ± 0.293		85	0.388	0.104 ± 0.298
	Haldal	69	0.232	−0.076 ± 0.544	0.039	27	0.333	0.003 ± 0.472	0.244	96	0.260	−0.054 ± 0.523	0.013
General	Clozapine	58	0.397	0.137 ± 0.328		27	0.593	0.213 ± 0.253		85	0.459	0.161 ± 0.307
	Haldal	69	0.362	0.071 ± 0.291	0.234	27	0.370	0.120 ± 0.259	0.189	96	0.365	0.085 ± 0.282	0.084

Combined samples = European-Americans + African-Americans; Responser, reduction rate ≥ 0.2; R, reduction rate of PANSS score; p, p-value for reduction rate comparison between clozapine and haloperidol Corrected α was set at 0.05 for PANSS Total score testing and 0.017 for PANSS subscore (i.e., Positive, Negative, and General scores) testing. Bold denotes p<α.